{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:29:03Z","timestamp":1794086943667,"version":"4.8.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["SCA-145103"],"award-info":[{"award-number":["SCA-145103"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ebiom.2019.08.041","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T08:21:07Z","timestamp":1566980467000},"page":"436-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease"],"prefix":"10.1016","volume":"47","author":[{"given":"Wouter N.","family":"Leonhard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish A.","family":"Kanhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioan-Andrei","family":"Iliuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bozovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien J.M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7858-1093","authenticated-orcid":false,"given":"York","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ebiom.2019.08.041_bb0005","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1681\/ASN.2018050493","article-title":"Prevalence estimates of polycystic kidney and liver disease by population sequencing","volume":"29","author":"Lanktree","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ebiom.2019.08.041_bb0010","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000421651","article-title":"Genetic heterogeneity of polycystic kidney disease in Europe","volume":"97","author":"Peters","year":"1992","journal-title":"Contrib Nephrol"},{"issue":"6","key":"10.1016\/j.ebiom.2019.08.041_bb0015","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1681\/ASN.2015060648","article-title":"Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease","volume":"27","author":"Hwang","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.ebiom.2019.08.041_bb0020","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.ebiom.2019.08.041_bb0025","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1681\/ASN.2015050583","article-title":"Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease","volume":"27","author":"Heyer","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.ebiom.2019.08.041_bb0030","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrneph.2011.109","article-title":"Why kidneys fail in autosomal dominant polycystic kidney disease","volume":"7","author":"Grantham","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1016\/j.ebiom.2019.08.041_bb0035","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1172\/JCI72272","article-title":"Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease","volume":"124","author":"Harris","year":"2014","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.ebiom.2019.08.041_bb0040","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/ki.2015.207","article-title":"A polycystin-centric view of cyst formation and disease: the polycystins revisited","volume":"88","author":"Ong","year":"2015","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.ebiom.2019.08.041_bb0045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.molmed.2014.01.004","article-title":"Polycystin\u22121: a master regulator of intersecting cystic pathways","volume":"20","author":"Fedeles","year":"2014","journal-title":"Trends Mol Med"},{"issue":"12","key":"10.1016\/j.ebiom.2019.08.041_bb0050","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1681\/ASN.2016040425","article-title":"Variable cyst development in autosomal dominant polycystic kidney disease: the biologic context","volume":"27","author":"Leonhard","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ebiom.2019.08.041_bb0055","first-page":"1157","article-title":"Lillian Jean Kaplan international prize for advancement in the understanding of polycystic kidney disease","volume":"64","author":"Grantham","year":"2003","journal-title":"Understanding polycystic kidney disease: a systems biology approach Kidney Int"},{"issue":"10","key":"10.1016\/j.ebiom.2019.08.041_bb0060","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ebiom.2019.08.041_bb0065","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.ebiom.2019.08.041_bb0070","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ebiom.2019.08.041_bb0075","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ebiom.2019.08.041_bb0080","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin\u22121, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.ebiom.2019.08.041_bb0085","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2009040421","article-title":"Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1","volume":"21","author":"Shillingford","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.ebiom.2019.08.041_bb0090","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.2011040340","article-title":"Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease","volume":"23","author":"Novalic","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.ebiom.2019.08.041_bb0095","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.ebiom.2019.08.041_bb0100","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ebiom.2019.08.041_bb0105","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1681\/ASN.2015030231","article-title":"2-deoxy-d-glucose ameliorates PKD progression","volume":"27","author":"Chiaravalli","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.ebiom.2019.08.041_bb0110","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1681\/ASN.2015020132","article-title":"Food restriction ameliorates the development of polycystic kidney disease","volume":"27","author":"Warner","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.ebiom.2019.08.041_bb0115","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ebiom.2019.08.041_bb0120","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2019.08.041_bb0125","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41573-019-0019-2","article-title":"AMP-activated protein kinase: the current landscape for drug development","volume":"18","author":"Steinberg","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.ebiom.2019.08.041_bb0130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin--mode of action and clinical implications for diabetes and cancer","volume":"10","author":"Pernicova","year":"2014","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"10.1016\/j.ebiom.2019.08.041_bb0135","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","article-title":"Metformin: from mechanisms of action to therapies","volume":"20","author":"Foretz","year":"2014","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.ebiom.2019.08.041_bb0140","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000488807","article-title":"A randomized clinical trial of metformin to treat autosomal dominant polycystic kidney disease","volume":"47","author":"Seliger","year":"2018","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1016\/j.ebiom.2019.08.041_bb0145","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cmet.2015.01.003","article-title":"Metformin action: concentrations matter","volume":"21","author":"He","year":"2015","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.ebiom.2019.08.041_bb0150","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cmet.2016.03.010","article-title":"Are metformin doses used in murine cancer models clinically relevant?","volume":"23","author":"Chandel","year":"2016","journal-title":"Cell Metab"},{"issue":"9","key":"10.1016\/j.ebiom.2019.08.041_bb0155","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.2337\/db16-0058","article-title":"The Na+\/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.ebiom.2019.08.041_bb0160","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","article-title":"The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration","volume":"5","author":"Villani","year":"2016","journal-title":"Mol Metab"},{"issue":"6083","key":"10.1016\/j.ebiom.2019.08.041_bb0165","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1126\/science.1215327","article-title":"The ancient drug salicylate directly activates AMP-activated protein kinase","volume":"336","author":"Hawley","year":"2012","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ebiom.2019.08.041_bb0170","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1042\/BJ20150125","article-title":"Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity","volume":"468","author":"Ford","year":"2015","journal-title":"Biochem J"},{"issue":"2","key":"10.1016\/j.ebiom.2019.08.041_bb0175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1042\/BJ20150122","article-title":"Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis","volume":"469","author":"O'Brien","year":"2015","journal-title":"Biochem J"},{"issue":"11","key":"10.1016\/j.ebiom.2019.08.041_bb0180","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41581-018-0051-1","article-title":"Metabolism and mitochondria in polycystic kidney disease research and therapy","volume":"14","author":"Padovano","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"10.1016\/j.ebiom.2019.08.041_bb0185","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1681\/ASN.2015030287","article-title":"Inhibition of activin signaling slows progression of polycystic kidney disease","volume":"27","author":"Leonhard","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"W1","key":"10.1016\/j.ebiom.2019.08.041_bb0190","doi-asserted-by":"crossref","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"10.1016\/j.ebiom.2019.08.041_bb0195","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2001-2-8-research0032","article-title":"Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application","volume":"2","author":"Li","year":"2001","journal-title":"Genome Biol"},{"issue":"1","key":"10.1016\/j.ebiom.2019.08.041_bb0200","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/cpmo.21","article-title":"Analysis of mtDNA\/nDNA ratio in mice","volume":"7","author":"Quiros","year":"2017","journal-title":"Curr Protoc Mouse Biol"},{"issue":"2","key":"10.1016\/j.ebiom.2019.08.041_bb0205","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2337\/dc07-1338","article-title":"Salsalate improves glycemia and inflammatory parameters in obese young adults","volume":"31","author":"Fleischman","year":"2008","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ebiom.2019.08.041_bb0210","doi-asserted-by":"crossref","first-page":"F806","DOI":"10.1152\/ajprenal.00653.2016","article-title":"Meta-analysis of polycystic kidney disease expression profiles defines strong involvement of injury repair processes","volume":"312","author":"Malas","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ebiom.2019.08.041_bb0215","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ceb.2014.11.002","article-title":"PPARs and ERRs: molecular mediators of mitochondrial metabolism","volume":"33","author":"Fan","year":"2015","journal-title":"Curr Opin Cell Biol"},{"issue":"2","key":"10.1016\/j.ebiom.2019.08.041_bb0220","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1091\/mbc.e16-08-0597","article-title":"The polycystins are modulated by cellular oxygen-sensing pathways and regulate mitochondrial function","volume":"28","author":"Padovano","year":"2017","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.ebiom.2019.08.041_bb0225","doi-asserted-by":"crossref","first-page":"e00337","DOI":"10.1128\/MCB.00337-17","article-title":"Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease","volume":"37","author":"Ishimoto","year":"2017","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ebiom.2019.08.041_bb0230","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14395","article-title":"microRNA\u221217 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism","volume":"8","author":"Hajarnis","year":"2017","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ebiom.2019.08.041_bb0235","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1681\/ASN.2011010084","article-title":"Macrophages promote cyst growth in polycystic kidney disease","volume":"22","author":"Karihaloo","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.ebiom.2019.08.041_bb0240","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1172\/JCI80467","article-title":"Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.ebiom.2019.08.041_bb0245","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1681\/ASN.2014010117","article-title":"Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis","volume":"25","author":"Anders","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.ebiom.2019.08.041_bb0250","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1681\/ASN.2015040405","article-title":"Necroinflammation in kidney disease","volume":"27","author":"Mulay","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.ebiom.2019.08.041_bb0255","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.2337\/db16-0564","article-title":"Salsalate (salicylate) uncouples mitochondria, improves glucose homeostasis, and reduces liver lipids independent of AMPK-\u03b21","volume":"65","author":"Smith","year":"2016","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.ebiom.2019.08.041_bb0260","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bph.14558","article-title":"The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease","volume":"176","author":"Lian","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ebiom.2019.08.041_bb0265","series-title":"Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers","article-title":"Center for drug evaluation and research","author":"U.S. Department of Health and Human Services, Food and Drug Administration","year":"2005"},{"issue":"5930","key":"10.1016\/j.ebiom.2019.08.041_bb0270","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2019.08.041_bb0275","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ebiom.2016.01.027","article-title":"Fatty acid oxidation is impaired in an orthologous mouse model of autosomal dominant polycystic kidney disease","volume":"5","author":"Menezes","year":"2016","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.ebiom.2019.08.041_bb0280","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1038\/s41598-018-20856-6","article-title":"A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed","volume":"8","author":"Lin","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ebiom.2019.08.041_bb0285","doi-asserted-by":"crossref","first-page":"F122","DOI":"10.1152\/ajprenal.00352.2017","article-title":"PPARalpha agonist fenofibrate enhances fatty acid beta-oxidation and attenuates polycystic kidney and liver disease in mice","volume":"314","author":"Lakhia","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"issue":"14","key":"10.1016\/j.ebiom.2019.08.041_bb0290","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2146\/ajhp120131","article-title":"Fenofibrate-associated nephrotoxicity: a review of current evidence","volume":"70","author":"Attridge","year":"2013","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"10.1016\/j.ebiom.2019.08.041_bb0295","first-page":"231","article-title":"Salsalate, an old, inexpensive drug with potential new indications: a review of the evidence from 3 recent studies","volume":"7","author":"Anderson","year":"2014","journal-title":"Am Health Drug Benefits"},{"issue":"10","key":"10.1016\/j.ebiom.2019.08.041_bb0300","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.tem.2013.06.002","article-title":"AMPK: mediating the metabolic effects of salicylate-based drugs?","volume":"24","author":"Steinberg","year":"2013","journal-title":"Trends Endocrinol Metab"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239641930564X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239641930564X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:32:14Z","timestamp":1778873534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235239641930564X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":60,"alternative-id":["S235239641930564X"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.08.041","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.08.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}